Your browser doesn't support javascript.
loading
Structural Refinement of Glucagon for Therapeutic Use.
Chabenne, Joseph R; Mroz, Piotr A; Mayer, John P; DiMarchi, Richard D.
Afiliação
  • Chabenne JR; Novo Nordisk Research Center, Indianapolis, Indiana 46241, United States.
  • Mroz PA; Department of Chemistry, Indiana University, Bloomington, Indiana 47405, United States.
  • Mayer JP; MCD Biology, University of Colorado, Boulder, Colorado 80309, United States.
  • DiMarchi RD; Novo Nordisk Research Center, Indianapolis, Indiana 46241, United States.
J Med Chem ; 63(7): 3447-3460, 2020 04 09.
Article em En | MEDLINE | ID: mdl-31774682
Glucagon counters insulin's effects on glucose metabolism and serves as a rescue medicine in the treatment of hypoglycemia. Acute hypoglycemia, a common occurrence in insulin-dependent diabetes, is the central obstacle to correcting high blood glucose, a primary cause of long-term microvascular complications. As a result, there has been a resurgence of interest in improved glucagon therapy, including nonconventional liquid formulations, alternative routes of administration, and novel analogs with optimized biophysical properties. These options collectively minimize the complexity of glucagon delivery and enable its application in ways not feasible with conventional emergency rescue kits. These advances have indirectly promoted the integrated use of glucagon agonism with other hormones in a manner that runs counter to the long-standing pursuit of glucagon antagonism. This review summarizes novel approaches to glucagon optimization, methods with potential application to the broader family of therapeutic peptides, where biophysical challenges may be encountered.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article